Marie-Pierre Dubé
Épidémiologie génétique et pharmacogénomique
- Professeure titulaire
-
Faculté de médecine - Département de médecine
- Professeure titulaire
-
École de santé publique - Département de médecine sociale et préventive
- Professeure accréditée
-
Faculté de médecine - Département de biochimie et médecine moléculaire
- Professeure accréditée
-
Faculté de médecine - Département de pharmacologie et physiologie
Médias
Portrait de chercheur : Dre Marie-Pierre Dubé 1/2
© 2014 Université de Montréal
Portrait de chercheur : Dre Marie-Pierre Dubé 2/2
© 2014 Université de Montréal
Portrait
Expertise de recherche
Mes intérêts de recherche portent sur l’étude génomique d’essais cliniques randomisés portant sur les maladies cardiovasculaires et métaboliques, ainsi que l’étude de l’impact du sexe et du genre sur l’efficacité et la sécurité des médicaments. Mon équipe de recherche est au Centre de Pharmacogénomique Beaulieu-Saucier de l’Université de Montréal situé à l'Institut de Cardiologie de Montréal. Je dirige un laboratoire de recherche en génomique de niveau clinique (www.pharmacogenomics.ca), ainsi que mon groupe de recherche en bio-informatique et génétique statistique (www.statgen.org). Nos études passées et en cours portent entre autres sur l’étude pharmacogénomique des statines, de l’inhibiteur de la CETP dalcetrapib, des antidiabétiques, des médicaments pour l'insuffisance cardiaque, ainsi que l’étude des anticoagulants oraux, dont la Cohorte québécoise de warfarine.
Biographie
Marie-Pierre Dubé est directrice du Centre de pharmacogénomique Beaulieu-Saucier de l’Université de Montréal. Elle est aussi chercheure à l'Institut de Cardiologie de Montréal où elle dirige une équipe de recherche en épidémiologie génétique et bio-informatique. Dre Dubé est Professeure titulaire au Département de médecine de l'Université de Montréal et détient une affectation secondaire au Département de médecine sociale et préventive et est membre accréditée aux départements de pharmacologie, de biochimie et au programme de bio-informatique. Elle dirige de nombreux étudiants aux études supérieures et postdoctorales dans ces programmes et enseigne l'épidémiologie génétique à l'Université de Montréal.
Dre Dubé a fait un B.Sc. en biologie (1994) et un Doctorat en génétique (1999) à l'Université McGill. Elle a effectué des études postdoctorales en épidémiologie génétique au Women’s College University of Toronto. Elle a également travaillé dans le secteur privé chez Xenon Pharmaceuticals à titre de chef des statistiques génétiques.
Dre Dubé détient la Chaire de recherche du Canada en Médecine de précision et analyse de données et a reçu de nombreux prix dont trois bourses de carrières des Fonds de recherche du Québec en Santé et le prix des Champions en Génétique du Canadian Gene Cure Foundation. Ses travaux de recherche sont financés entre autres par les Instituts de recherche en santé du Canada et le Gouvernement du Québec, et elle a publié plus de 170 articles dans des journaux scientifiques à comité de lecture. Ses travaux portent sur l’analyse de données recueillies dans le cadre d’études cliniques sur les maladies cardiovasculaires et métaboliques et sur l’impact du sexe et du genre sur l’efficacité et la sécurité des médicaments.
Prix et distinctions
2020 - 2027 : Chaire de recherche du Canada (CRC) en Médecine de précision et analyse de données
2015 - 2018 Chercheur Boursier Senior, FRQS
2012 : Prix Champions de Génétique, Canadian Gene Cure Foundation
2009 - 2013 : Chercheur boursier junior 2, FRQS
2009 : Prix pour la qualité de l'enseignement, Merck Frost Schering Plough
2008 : Bourse d'Excellence Martial Bourassa
2005 - 2009 : Chercheur boursier junior 1, FRQS
2004 : Bourse salariale, département de médecine de l’Université de Montréal
Formation
- 2001 — Postdoctorat — Épidémiologie et biostatistique — University of Toronto
- 1994 — Baccalauréat — Biologie et autres sciences connexes — Université McGill
- 2000 — Doctorat — Génétique — Université McGill
Pour en savoir plus…
- Équipe de recherche de Marie-Pierre Dubé
- Centre de Pharmacogénomique Beaulieu-Saucier de l'Université de Montréal
- 2015-01-13 Première mondiale : découverte d'une thérapie personnalisée pour les maladies cardiovasculaires
- Portrait de chercheur - Marie-Pierre Dubé : une femme de défis
- 29-10-2014 L'effet des statines influencé par le profil génétique
Affiliations et responsabilités
Affiliations de recherche
Unités de recherche
Membre
Établissements affiliés
- Institut de cardiologie de Montréal (ICM)
Enseignement et encadrement
Enseignement
Cours siglés (session en cours uniquement)
Programmes
Encadrement
Thèses et mémoires dirigés (dépôt institutionnel Papyrus)
Impact des antibiotiques céfprozil et céfoxitine sur le microbiote Eggerthella lenta, lié au métabolisme du cardiotonique digoxine
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
The risk of cancer in statin users : a clinical and genetic approach
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
Apport du gène Transcription factor 7-like 2 (TCF7L2) au diabète induit par les statines
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
Genetic association study of plasma creatine kinase levels in the Montreal Heart Institute Hospital Cohort
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
Étude pharmacogénomique de la warfarine et de l'activité physique
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
Rôles des polymorphismes génétiques dans la détermination de la dose individuelle de la warfarine chez les patients traités avec de l’amiodarone
Cycle : Maîtrise
Diplôme obtenu : M. Sc.
Étude sur le rôle des mutations de novo dans l’étiologie génétique de la schizophrénie
Cycle : Doctorat
Diplôme obtenu : Ph. D.
Approches bio-informatiques appliquées aux technologies émergentes en génomique
Cycle : Doctorat
Diplôme obtenu : Ph. D.
Genomic architecture of sickle cell disease clinical variation in children from West Africa : a case-control study design
Cycle : Doctorat
Diplôme obtenu : Ph. D.
Projets
Projets de recherche
COLCOT-T2D : Colchicine for Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes
Canada Research Chair in Precision Medicine Data Analysis
Complex genetics of hypertrophic cardiomyopathy: Towards an integration of polygenic risk in clinical care
Study of the effect of sex on drugs dosing, concentrations and pharmacogenomics
Precision medicine in diabetes: Pharmacogenetic studies of large randomised controlled trials of diabetes therapies. (MRC PA: Ewan Pearson)
Comparing the effects of cognitive training and physical exercise on cognition, cerebral autoregulation and cerebral vasoreactivity in men and women with heart failure
Determining the etiologies of age-related clonal hematopoiesis (ARCH), a new biomarker of cancer and cardiovascular disease development: focus on the roles of inflammation and genetic predisposition.
Développement d'un modèle de prédiction pour optimiser l'usage des anticoagulants oraux (DOACs) en pratique clinique. Demande en évaluation à la Fondation des maladies du coeur et des accidents cérébr.. / Réseau québécois de recherche sur les médicaments
Recherche en médecine de précision portant sur le diabète et les maladies cardiovasculaires
Mendelian randomization study of CETP and ADCY9 in cardiovascular disease
Effectiveness and safety of Direct Oral AntiCoagulants (DOACs) among older adults with atrial fibrillation
Inherited chromosomally-integrated human herpesvirus 6 and cardiovascular diseases
Infléchir l'athérosclérose par la médecine de precision.
Sex differences in the treatment of heart failure
Suvention FICM 2015-2018
PSYCHOLOGICAL BURDEN AND PATHOLOGICAL AGING IN INDIVIDUALS WITH AND WITHOUT CARDIOVASCULAR DISEASE
Colchicine Cardiovascular Outcomes Trial
Increased risk of cardiovascular disease in women with inherited chromosomally-integrated human herpesvirus 6
Programme ARTERIA: Personnalisation des diagnostics et thérapies cardiovasculaires
PHARMACOGENOMIC TESTING OF ATORVASTATIN EFFICACY AND TOXICITY IN SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
INCREASING VITAMIN K INTAKE TO IMPROVE LONG-TERM ANTICOAGULATION STABILITY IN PATIENTS TREATED WITH WARFARIN
Colchicine Cardiovascular Outcomes Trial
Études pharmacogénomiques vers une thérapie personnalisée en cardiologie
Increased risk of cardiovascular disease in women with inherited chromosomally-integrated human herpesvirus 6
GENOMIC STUDY OF BLEEDING RISK WITH WARFARIN
PERSONALIZED MEDECINE STRATEGIES FOR MOLECULAR DIAGNOSTICS AND TARGETED THERAPEUTICS OF CARDIOVASCULAR DISEASES
PERSONALIZED MEDECINE STRATEGIES FOR MOLECULAR DIAGNOSTICS AND TARGETED THERAPEUTICS OF CARDIOVASCULAR DISEASES
Personalized medicine strategies for molecular diagnostics and targeted therapeutics of cardiovascular diseases
Description
This project will deliver pharmacogenomic tests for more efficient management of patients with cardiovascular disease. By bringing our understanding of genes that influence cardiovascular drug efficacy and toxicity into the clinical setting, we can provide guidance to health professionals in the selection and dosing of a specific drug, resulting in improved health care.
The project will benefit the Canadian healthcare system substantially by:
- Improving the treatment of patients while reducing harmful-side effects
- Increasing patient confidence (and adherence) to medications (more likely to avoid or accurately identify side effects and derive benefits)
- Reducing costs for the healthcare system (by reducing ineffective use of drugs in non-responsive patients and unnecessary spending by healthcare payers)
- Increasing reimbursement, and thus market access, for new drugs due to more effective use of drugs based on pharmacogenomic tests
Of note, 80,000 Canadians died in 2010 from cardiovascular disease, which accounts for 35% of all deaths in the country. Currently, 1.3 million Canadians suffer from cardiovascular disease causing a serious economic burden of $22.2 billion/year, representing the highest healthcare costs in Canada.
Integrative genomic and genetic analyses of consanguineous Pakistani pedigrees aggregated with psychotic/affective disorders
Description
Résumé
Pakistan has the highest rate of consanguineous marriage in the world due to historical, religious, cultural and social reasons. A long history of such intracommunity and/or consanguineous marriage has divided the Pakistani population into many rural isolated clans, segregated by geography, language, religion and tribal group, and creating genetic isolates with individual mutation profiles. Consanguineous pedigrees have been successfully used in mapping rare recessive Mendelian disorders in the past. However, the potential influence of such long standing endogamous and consanguineous unions on overall levels of homozygosity genomewide and genetic disease profiles, especially for more common diseases, for such particular genetic isolates remains largely underinvestigated. Schizophrenia (SCZ), schizoaffective (SAF) and bipolar (BP) disorders are common brain diseases in all populations with largely unknown etiology and molecular pathogenesis pathways. Genetic factors have been considered important contributing causes and have been the focus of intensive research efforts in the past decades. To date, the genetic architecture of these three main psychiatric disorders remain largely unknown and very few convincing genetic factors have been identified. We propose to launch a thorough genomewide genetic investigation of 10 collected and clinically well characterized large consanguineous pedigrees from Pakistan to identify causative genetic variants contributing to these major mental disorders. The study of such isolated consanguineous populations with major psychiatric disorders offers a unique opportunity to identify transmitted mutations contributing to SCZ etiology. Thorough genetic and genomic investigations in these pedigrees will also help us better understand the effect of long-term endogamous/consanguineous marriage on the genetic profile and structure of such populations, particularly for complex genetic traits like SCZ.
(Bourse Michel Cameron) Développement d'un panel pharmacogénomique et élaboration d'une base de données translationnelle
Développement d'un panel pharmacogénomique et élaboration d'une base de données translationnelle
Pharmacogenomic testing of atorvastatin efficacy and toxicity in secondary prevention of cardiovascular diseases
Description
Résumé
In Canada, the number of individuals coping with heart disease is steadily increasing and now affects more than 1.3 million individuals. Cardiovascular disease (CVD) represents the most important health care spending in Canada and costs the Canadian economy $20.9 billion/year. Current standard of care requires patients with heart disease to be treated with lipid-lowering medications known as statins. Still, despite being treated with highly potent statins, the risk of cardiovascular events remained very elevated for these patients. We are at the forefront of CVD pharmacogenomic testing and are currently involved in several clinical trials and genetic consortia that aim at developing personalized medical tools to optimize management of CVD in Canada and around the world. Our objective is to take advantage of our increasing knowledge of the human genome along with the most recent technologies used for surveying it to identify genes that influence both the efficacy of these drugs and the risk of CVD in this population. On top of opening novel research opportunities on the newly discovered genes that influence CVD, this project will directly improve personal health by delivering molecular diagnostic tools able to identify patients that are likely to benefit the most from high-dose statin therapy. As a consequence, this approach will help determine whether or not a specific subgroup of patients do not drive any benefits from atorvastatin therapy and therefore expose themselves to avoidable potential side-effects in such a way that they are likely to derive more risk than benefits from atorvastatin therapy. The identification of these non-responsive patients could help avoid a considerable amount of useless prescriptions and provide substantial savings for healthcare systems across Canada and around the world.
NOVEL APPROACHES TO THE PREDICTION, DIAGNOSIS AND TREATMENT OF CARDIAC LATE EFFECTS IN SURVIVORS OF CHILDHOOD CANCER
(RESEAUTETE) - THE INTEGRATED RESEARCH NETWORK ON PERINATOLOGY
SUBVENTION FICM 2013-2014
EMERGING TEAM IN DEVELOPMENT OF STRATEGIES FOR UPTAKE AND ANALYSIS OF NANOSEQUENCING-DERIVED DATA SETS AND LINKING TO DISEASE
PHARMACOGENETIC STUDY OF WARFARIN
Pharmacogenetic Study of Warfarin: Identification of patients on blood-thinner therapy who are at risk of serious adverse events
Description
Résumé
Warfarin is the most widely prescribed blood thinner medication for the treatment and prevention of blood clots. Its use, however, is greatly complicated by the drug's narrow therapeutic dose range and by the extensive variation in safe doses among different individuals to avoid exposing patients to clots formation or to bleeding events. Recent studies showed that two genes, together with environmental factors, can explain some of the variability between patients. New blood thinner medications are being developed that could eventually provide an alternative to warfarin treatment. In order to identify patients who are most likely to be exposed to serious bleeding or clot formation we propose to evaluate the genetic and clinical determinants of adverse responses to warfarin treatment. These include: (i) severe and potentially fatal bleeding, the most serious adverse response; (ii) major complications related to clot formation; and (iii) fluctuations in the International Normalised Ratio (INR), a parameter used to monitor warfarin treatment in order to establish the safe therapeutic dosage for each patient.
This study will recruit 2,500 patients initiating warfarin therapy over a 2-year period. Patients will be selected from the warfarin clinics of 4 greater-Montreal area. They will be followed-up for 1 year as part of this research project. The prediction of adverse events in warfarin therapy is expected to allow a better management of treatment with blood thinner medications. This effort offers great potential for the improvement of personal and public health.
EMERGING TEAM IN DEVELOPMENT OF STRATEGIES FOR UPTAKE AND ANALYSIS OF NANOSEQUENCING-DERIVED DATA SETS AND LINKING TO DISEASE
GENETIQUE EPIDEMIOLOGIQUE ET STATISTIQUE
Rayonnement
Publications et communications
Publications
Articles choisis
(* étudiant ou membre de l'équipe de recherche)
- A genetic model of ivabradine recapitulates results from randomized clinical trials. MA Legault, J Sandoval, S Provost, A Barhdadi, LP Lemieux Perreault, S Shah, RT Lumbers, S de Denus, B Tyl, JC Tardif, Dubé MP, PLoS One. 2020 Jul 21;15(7):e0236193. PMID: 32692755
- High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Busque L, Sun M, Buscarlet M, Ayachi S, Feroz Zada Y, Provost S, Bourgoin V, Mollica L, Meisel M, Hinterleitner R, Jabri B, Dubé MP†, Tardif JC†. Blood Adv. 2020 Jun 9;4(11):2430-2438. PMID: 32492156
- Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. Tardif JC, Dubé MP, Pfeffer MA, Waters DD, Koenig W, Maggioni AP, McMurray JJV, Mooser V, White HD, Heinonen T, Black DM, Guertin MC; dal-GenE Investigators. Am Heart J 2020 Jan 17;222:157-165. PMID: 32087417
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie MA, Dubé MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. N Engl J Med. 2019 Dec 26;381(26):2497-2505. PMID: 31733140
- Lipoprotein (a), arterial inflammation, and PCSK9 inhibition. Tardif JC, Rhéaume E, Rhainds D, Dubé MP. Eur Heart J. 2019 Sep 1;40(33):2782-2784. PMID: 30838412
- Association of Chromosome 9p21 with Subsequent Coronary Heart Disease Events: A GENIUS-CHD Study of Individual Participant Data. Patel RS, …, Asselbergs FW. Circ Genom Precis Med. 2019 Apr;12(4):e002471. PMID: 30897348
- Subsequent Event Risk in Individuals with Established Coronary Heart Disease: Design and Rationale of the GENIUS-CHD Consortium. Patel R, …, Asselbergs FW. Circ Genom Precis Med. 2019 Apr;12(4):e002470. PMID: 30896328
- Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort. Shahabi P*, Lamothe F*, Dumas S*, Rouleau-Mailloux É*, Feroz Zada Y*, Provost S*, Asselin G*, Mongrain I*, Valois D*, Gaulin Marion MJ*, Lemieux Perreault LP*, Perreault S, Dubé MP. Pharmacogenomics J. 2019 Apr;19(2):147-156. PMID: 29298995
- Pharmacogenetic content of commercial genome-wide genotyping arrays. Lemieux Perreault LP*, Zaïd N*, Cameron M*, Mongrain I*, Dubé MP. Pharmacogenomics. 2018 Oct;19(15):1159-1167. Epub 2018 Oct 1. PMID: 30272537
- Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype. Pfeffer MA, Dubé MP, Tardif JC. JAMA Cardiol. 2018 Sep 1;3(9):897.. PMID: 30090919
- Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines. Levinsson A*, Dubé MP†, Tardif JC, de Denus S†. ESC Heart Fail. 2018 Oct;5(5):745-754. Review. PMID: 29916560
- Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Buscarlet M, Provost S*, Feroz Zada Y*, Bourgoin V, Mollica L, Dubé MP, Busque L. Blood. 2018 Jul 19;132(3)277-280. PMID: 29764839
- Pharmacogenomics of blood lipid regulation. Legault MA*, Tardif JC, Dubé MP. Pharmacogenomics. 2018 May;19(7):651-665. PMID: 29706123
- A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure. Denus S, Dubé MP, Fouodjio R*, Huynh T, LeBlanc MH, Lepage S, Sheppard R, Giannetti N, Lavoie J, Mansour A, Provost S*, Normand V, Mongrain I*, Langlois M*, O'Meara E, Ducharme A, Racine N, Guertin MC, Turgeon J, Phillips MS, Rouleau JL, Tardif JC, White M; CANDIID II investigators. Pharmacogenomics. 2018 May;19(7):599-612. PMID: 29701105
- Rationale, design and preliminary results of the Quebec Warfarin Cohort Study. Perreault S, Shahabi P*, Côté R, Dumas S*, Rouleau-Mailloux É*, Feroz Zada Y*, Provost S*, Mongrain I*, Dorais M, Huynh T, Kouz S, Diaz A, Blostein M, de Denus S, Turgeon J, Ginsberg J, Lelorier J, Lalonde L, Busque L, Kassis J, Talajic M, Tardif JC, Dubé MP. Clin Cardiol. 2018 May;41(5):576-585 PMID: 29542828
- Exome-wide association study of plasma lipids in >300,000 individuals. Liu DJ, …, Kathiresan S. Nat Genet. 2017 Dec;49(12):1758-1766, PMID: 29083408
- CKing Precision in the Interpretation of Diagnostic Biomarkers. de Denus S, Tardif JC, Dubé MP. Circ Cardiovasc Genet. 2017 Aug;10(4). pii: e001874. PMID: 28790156
- DNMT3A and TET2 dominate clonal hematopoiesis, demonstrate benign phenotypes and different genetic predisposition. Buscarlet M, Provost S*, Feroz Zada Y*, Barhdadi A*, Bourgoin V, Lépine G, Mollica L, Szuber N, Dubé MP, Busque L. Blood. 2017 Aug 10;130(6):753-762, PMID: 28655780
- CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. de Denus S, Rouleau JL, Mann DL, Huggins GS, Pereira NL, Shah SH, Cappola TP, Fouodjio R*, Mongrain I*, Dubé MP. Pharmacogenomics J. 2018 Apr;18(2) :232-237. PMID: 28440343
- genipe: An automated genome-wide imputation pipeline with automatic reporting and statistical tools. Lemieux Perreault LP*, Legault MA*, Asselin G*, Dubé MP. Bioinformatics. 2016, 32(23): 3661-3663 PMID: 27497439
- Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. Postmus I, …, Krauss RM. J Med Genet. 2016 Dec;53(12):835-845. PMID: 27587472
- Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance with Clinical Outcomes. Tardif JC, Rhainds D, Brodeur M, Feroz Zada Y*, Fouodjio R*, Provost S*, Boulé M, Alem S, Grégoire JC, L'Allier PL, Ibrahim R, Guertin MC, Mongrain I*, Olsson AG, Schwartz GG, Rhéaume É, Dubé MP. Circ Cardiovasc Genet. 2016 Aug;9(4):340-8. PMID: 27418594
- Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. Myocardial Infarction Genetics CARDIoGRAM Exome Consortia Investigators: Stitziel NO, …, Schunker H. New England Journal of Medicine, March 24; 374(12):1134-44, 2016. PMID: 26934567
- A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of 3 clinical trials. de Denus S, Rouleau J, Mann D, Huggins G, Cappola T, Shah S, Keleti J, Feroz Zada Y*, Provost S*, Barhdadi A*, Phillips M, Normand V*, Mongrain I*, Dubé MP. Pharmacogenomics J. 2016 Mar;17(2):192-200 PMID: 26927285
- Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Dubé MP, de Denus S, Tardif JC. Cardiovascular Drugs and Therapy, 2016 Feb;30(1):59-64; PMID: 26768480
- Impact of regular physical activity on weekly warfarin dose requirement. Rouleau-Mailloux É*, Shahabi P*, Dumas S*, Feroz Zada Y*, Provost S*, Hu J*, Nguyen J*, Bouchama N*, Mongrain I*, Talajic M, Tardif JC, Perreault S, Dubé MP. J Thromb Thrombolysis. 2016 Feb;41(2):328-35, PMID: 26238769
- Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib. Tardif JC, Rhéaume E, Lemieux Perreault LP*, Grégoire JC, Feroz Zada Y*, Asselin G*, Provost S*, Barhdadi A*, Rhainds D, L’Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I*, Schwartz GG, Dubé MP. Circ Cardiovasc Genet, 2015 Apr;8(2):372-82; PMID: 25583994
H-index = 49
Liste complète des publiations : https://scholar.google.com.au/citations?user=Yz1gObIAAAAJ&hl=en&oi=ao
Communications
- La génétique et les médicaments. TEDx Pôle Maisonneuve, published online on Dec 21 2016.
- Can Medicine be Personalized Without Sex and Gender. Featured Research. Canadian Institutes of Health Research, Institute Gender and Health. Interviewed by Rachel MacNeil. First published August 2016.
- Marie-Pierre Dubé: une femme de défis. Portraits de chercheurs (Recherchers’ profiles), published by the Université de Montréal, appears online and was distributed to the broad university community. Interviewed by Annik Chainey. First published June 2015.
- La pilule aux yeux bleus. Les années lumière. Weekly science radio program on Ici Radio-Canada. Interviewed by Yannick Villedieu. First broadcast February 2009.
- Des médicaments sur mesure pour chaque patient ? Les promesses de la pharmacogénomique. Le Code Chastenay, Télé-Québec, Émission #7. Interview given as part of a televised documentary science series, aired for the first time February 18 2008. Interviewed by Véronique Morin.
Disciplines
- Épidémiologie et biostatistique
- Génétique
- Pharmacologie
- Cardiologie
Champ d’expertise
- Génétique
- Génomique
- Usage optimal des médicaments
- Thérapie génique
- Maladies cardiovasculaires